DE69220517D1 - Chinoline enthaltende Ketosäure als Leukotrien-Antagonisten - Google Patents

Chinoline enthaltende Ketosäure als Leukotrien-Antagonisten

Info

Publication number
DE69220517D1
DE69220517D1 DE69220517T DE69220517T DE69220517D1 DE 69220517 D1 DE69220517 D1 DE 69220517D1 DE 69220517 T DE69220517 T DE 69220517T DE 69220517 T DE69220517 T DE 69220517T DE 69220517 D1 DE69220517 D1 DE 69220517D1
Authority
DE
Germany
Prior art keywords
acid containing
keto acid
leukotriene antagonists
quinolines
containing quinolines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69220517T
Other languages
English (en)
Other versions
DE69220517T2 (de
Inventor
Michel L Belley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Merck Frosst Canada and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada and Co filed Critical Merck Frosst Canada and Co
Application granted granted Critical
Publication of DE69220517D1 publication Critical patent/DE69220517D1/de
Publication of DE69220517T2 publication Critical patent/DE69220517T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE69220517T 1991-02-21 1992-02-20 Chinoline enthaltende Ketosäure als Leukotrien-Antagonisten Expired - Fee Related DE69220517T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65893191A 1991-02-21 1991-02-21

Publications (2)

Publication Number Publication Date
DE69220517D1 true DE69220517D1 (de) 1997-07-31
DE69220517T2 DE69220517T2 (de) 1997-12-18

Family

ID=24643302

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69220517T Expired - Fee Related DE69220517T2 (de) 1991-02-21 1992-02-20 Chinoline enthaltende Ketosäure als Leukotrien-Antagonisten

Country Status (17)

Country Link
EP (1) EP0500360B1 (de)
JP (1) JPH0788361B2 (de)
KR (1) KR920016423A (de)
CN (1) CN1065062A (de)
AT (1) ATE154801T1 (de)
AU (1) AU648385B2 (de)
CA (1) CA2061675C (de)
CS (1) CS47192A3 (de)
DE (1) DE69220517T2 (de)
ES (1) ES2104821T3 (de)
FI (1) FI920734A (de)
HU (1) HU9200552D0 (de)
IE (1) IE920499A1 (de)
IL (1) IL100985A0 (de)
MX (1) MX9200714A (de)
NO (1) NO920681L (de)
ZA (1) ZA921232B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
GB9216768D0 (en) * 1992-08-07 1992-09-23 Leo Pharm Prod Ltd Chemical compounds
WO1996033717A1 (en) * 1995-04-28 1996-10-31 Takeda Chemical Industries, Ltd. Therapeutic composition for arthritis
WO1998008820A1 (fr) * 1996-08-26 1998-03-05 Yamanouchi Pharmaceutical Co., Ltd. Composes de benzenesulfone et sels de ces derniers
AU742237B2 (en) * 1998-07-14 2001-12-20 Alcon Manufacturing Limited Use of 11-(3-dimenthylaminopropylidene)-6,11-dihydrodibenz (B,E)oxepin-2-acetic acid for the manufacture of medicament for treating non-allergic opthalmic inflammatory disorders and for the prevention of ocular neovascularization
WO2005105751A1 (en) * 2004-04-21 2005-11-10 Teva Pharmaceutical Industries Ltd. Processes for preparing montelukast sodium
ITMI20050247A1 (it) 2005-02-18 2006-08-19 Chemi Spa Processo per la preparazione di montelukast
WO2006131782A1 (en) * 2005-06-07 2006-12-14 Glade Organics Private Limited Process for the manufacture of methyl-2-(3-(2-(7-chloro-2-quinolinyl-ethenyl)-phenyl)-3-oxopropyl) benzoate
EP1904448B1 (de) 2005-07-05 2011-02-02 Teva Pharmaceutical Industries, Ltd. Reinigung von montelukast
AR057909A1 (es) * 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
CN101365683A (zh) * 2005-11-18 2009-02-11 斯索恩有限公司 制备孟鲁司特及其中间体的方法
EP2059509A2 (de) * 2006-09-15 2009-05-20 Cipla Limited Verfahren zur herstellung von montelukast, und zwischenprodukte dafür
ES2320077B1 (es) 2007-07-31 2010-02-26 Moehs Iberica, S.L. Proceso de preparacion de un antagonista de leucotrienos y de un intermedio del mismo.
CN101851196B (zh) * 2010-05-28 2011-07-27 中国科学院昆明植物研究所 2-(1h)喹啉酮衍生物,其药物组合物及其制备方法和用途
KR20140108627A (ko) * 2011-07-26 2014-09-12 썬 파마 어드밴스트 리서치 컴패니 리미티드 퀴놀린-, 퀸옥살린 또는 벤조티아졸계 시스테이닐 류코트리엔 길항물질 (ltc4)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE59889B1 (en) * 1986-02-14 1994-04-20 Merck Frosst Canada Inc 2-substituted quinoline dioic acids
EP0318093A3 (de) * 1987-11-25 1990-12-05 Merck Frosst Canada Inc. Diarylchinolindicarbonsäure und ihre Verwendung als Arzneimittel
EP0349062A1 (de) * 1988-06-27 1990-01-03 Merck Frosst Canada Inc. Chinolinetheralkansäuren
NZ233752A (en) * 1989-05-24 1993-05-26 Merck Frosst Canada Inc Substituted quinoline derivatives, preparation and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
KR920016423A (ko) 1992-09-24
IL100985A0 (en) 1992-11-15
AU1111992A (en) 1992-08-27
NO920681D0 (no) 1992-02-20
ES2104821T3 (es) 1997-10-16
FI920734A0 (fi) 1992-02-20
DE69220517T2 (de) 1997-12-18
JPH0525135A (ja) 1993-02-02
CN1065062A (zh) 1992-10-07
CA2061675A1 (en) 1992-08-22
ZA921232B (en) 1992-10-28
HU9200552D0 (en) 1992-05-28
ATE154801T1 (de) 1997-07-15
EP0500360B1 (de) 1997-06-25
AU648385B2 (en) 1994-04-21
IE920499A1 (en) 1992-08-26
FI920734A (fi) 1992-08-22
NO920681L (no) 1992-08-24
MX9200714A (es) 1992-10-01
JPH0788361B2 (ja) 1995-09-27
CA2061675C (en) 2002-12-17
EP0500360A1 (de) 1992-08-26
CS47192A3 (en) 1992-10-14

Similar Documents

Publication Publication Date Title
DE69319482T2 (de) Chinolinderivate als Leukotrien-Antagoniste
LV12187A (lv) Nepiesatinatas hidroksialkiletas hinolina rindas karbonskabes
DE69220517D1 (de) Chinoline enthaltende Ketosäure als Leukotrien-Antagonisten
DE69328540T2 (de) Diaryl 5,6-kondensierte heterozyklische Säuren als Leukotrienantagonisten
ATE128969T1 (de) Hydroxyalkylchinolin äther säure als leukotrien- antagoniste.
DE69833429D1 (de) Chinolin-leukotrien-antagonisten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK FROSST CANADA & CO, KIRKLAND, QUEBEC, CA

8339 Ceased/non-payment of the annual fee